Related Experiment Video
Updated: May 28, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Colchicine for secondary prevention in patients with acute coronary syndrome: A systematic review and meta-analysis
Safia Shaikh1, Mohammad Hamza2, Sivaram Neppala3
1Washington University in St Louis, St Louis, MO, USA.
Insights
Colchicine, an anti-inflammatory drug, reduced hospitalizations in acute coronary syndrome (ACS) patients but increased gastrointestinal side effects. Further research is needed to confirm its clinical benefits in cardiovascular disease prevention.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Coronary artery disease (CAD) remains a global health challenge, with inflammation playing a key role in atherosclerosis.
- Colchicine, an anti-inflammatory medication, is being investigated for its potential to prevent CAD events after acute coronary syndrome (ACS).
Approach:
- A systematic review and meta-analysis of nine studies involving 7260 patients was conducted.
- Searched PubMed and Embase for trials comparing colchicine with standard medical treatment in ACS patients up to April 2024.
- Analyzed outcomes including major adverse cardiovascular events (MACE), recurrent ACS, cardiovascular death, heart failure, stroke, hospitalizations, and gastrointestinal side effects.
Key Points:
- Colchicine treatment in ACS patients led to a significant reduction in re-hospitalizations (OR 0.52).
- However, colchicine use was associated with a significant increase in gastrointestinal side effects (OR 2.10).
- No significant differences were observed in cardiovascular death, MACE, stroke, recurrent ACS, or congestive heart failure incidence.
Conclusions:
- Adding colchicine to standard therapy for ACS patients reduces hospitalizations but increases gastrointestinal adverse events.
- Further prospective trials are necessary to validate these findings and assess the long-term clinical impact of early colchicine intervention in ACS.
Background:
Despite optimal therapy, coronary artery disease (CAD) remains a significant public health concern worldwide. Studies have increasingly recognized the role of inflammation in atherosclerosis. Colchicine, a potent anti-inflammatory drug commonly used to treat gout, and pericarditis is being evaluated in this study for its safety and efficacy in preventing CAD following an acute coronary syndrome (ACS).
Methods:
We searched PubMed and Embase for studies up to April 2024 comparing colchicine to standard medical treatment in ACS patients. Primary outcomes included major adverse cardiovascular events (MACE) and recurrent ACS, while secondary outcomes were cardiovascular death, congestive heart failure (CHF), stroke, hospitalizations, and gastrointestinal (GI) side effects. Data were pooled using a random-effects model.
Results:
We included nine studies with a pooled sample size of 7260 patients. The mean age was 60.1 (±11.8) years, with 19.3 % females and a mean follow-up duration of 8.5 (±6) months. Patients who received colchicine treatment demonstrated a reduced risk of re-hospitalizations (OR 0.52 [0.34-0.81]) but had increased GI effects (OR 2.10 [1.20-3.68]). There was no significant difference in cardiovascular death (OR 1.17 [0.52-2.63]), MACE (OR 0.68 [0.45-1.01]), stroke (OR 0.46 [0.18-1.18]), recurrent ACS (OR 0.55 [0.28-1.09]) and the incidence of CHF (OR 0.90 [0.38-2.12]) between patients treated with colchicine versus standard medical treatment.
Conclusion:
Adding colchicine to standard medical therapy in ACS patients significantly reduced hospitalizations but is associated with increased GI side effects. Further prospective trials are required to validate these findings and determine if early intervention with colchicine treatment improves clinical outcomes in ACS patients.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...